Baker R P, Al-Kubati W, Atuf M, Phillips R K S
Department of Coloproctology, Clarendon Wing, Leeds General Infirmary, Great George Street, Leeds, West Yorkshire, UK.
Tech Coloproctol. 2007 Dec;11(4):343-5. doi: 10.1007/s10151-007-0378-2. Epub 2007 Dec 3.
Nicorandil is a potassium channel activator used in the prevention and long-term treatment of angina pectoris. It is widely prescribed and its use is supported by data from powerful randomised controlled trials. The colorectal community is becoming increasingly aware of a subgroup of patients with anal ulceration and other gastrointestinal manifestations of nicorandil use.
This study is a retrospective review of patients identified as having nicorandil-induced perianal ulceration. We report our experience of 11 patients.
All eleven patients experienced severe debilitating ulceration of the perianal area and perineum. Multiple therapies were tried unsuccessfully before the association with nicorandil was recognised. Upon recognition of the association of nicorandil with these ulcers, the therapy was stopped resulting in resolution of the perianal symptoms.
Nicorandil is a rare cause of severe perianal ulceration. This association should be recognised as these ulcers are resistant to other forms of treatment but heal well on ceasing nicorandil use.
